{"url_path":"/sec/rlay/8-k/2026-05-21/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/1812364/0001193125-26-234862-index.html","accession_number":"0001193125-26-234862","cik":"0001812364","ticker":"RLAY","issuer_name":"Relay Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1812364/0001193125-26-234862-index.html","primary_entity_key":"0001812364","primary_entity_name":"Relay Therapeutics, Inc."},"word_count":121,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\n1.1\n  \n[Underwriting Agreement, dated as of May 20, 2026, by and among the Company, Jefferies LLC and TD Securities (USA) LLC, as representatives of the several Underwriters listed on Schedule 1 thereto.](d128795dex11.htm)\n\n5.1\n  \n[Opinion of Goodwin Procter LLP regarding the issue of Common Stock being registered.](d128795dex51.htm)\n\n23.1\n  \n[Consent of Goodwin Procter LLP (included in Exhibit 5.1).](d128795dex51.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within Inline XBRL document).\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\n \nRELAY THERAPEUTICS, INC.\n\nDate: May 21, 2026\n \n\n \nBy:\n \n\n/s/ Soo-Yeun Lim\n\n \n\n \n\n \nSoo-Yeun Lim\n\n \n\n \n\n \nGeneral Counsel"}